Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 63, Issue 6, Pages 2958-2973Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b01624
Keywords
-
Categories
Funding
- JDRF [15-2013-582]
- GNF
Ask authors/readers for more resources
Autoimmune deficiency and destruction in either beta-cell mass or function can cause insufficient insulin levels and, as a result, hyperglycemia and diabetes. Thus, promoting beta-cell proliferation could be one approach toward diabetes intervention. In this report we describe the discovery of a potent and selective DYRK1A inhibitor GNF2133, which was identified through optimization of a 6-azaindole screening hit. In vitro, GNF2133 is able to proliferate both rodent and human beta-cells. In vivo, GNF2133 demonstrated significant dose-dependent glucose disposal capacity and insulin secretion in response to glucose-potentiated arginine-induced insulin secretion (GPAIS) challenge in rat insulin promoter and diphtheria toxin A (RIP-DTA) mice. The work described here provides new avenues to disease altering therapeutic interventions in the treatment of type 1 diabetes (T1D).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available